Firebrick Pharma Limited · ASX:FRE
Firebrick Pharma — Investor Presentation (June 2025)
20 slides from Firebrick Pharma's investor presentation, Jun 23, 2025
Slide 1: The world needs Nasodine
For personal use only The world needs Nasodine Firebrick Pharma ASX: FRE firebrickpharma.com Investor Presentation 23 June 2025 Approved for release by Dr Peter Molloy, Executive Chairman & CEO of Firebrick Pharma Limited
Slide 2: Notice and Disclaimer
NOTICE AND DISCLAIMER This presentation is provided for information purposes only. The information in this presentation is in a summary form, does not purport to be complete and is not intended to be relied upon as advice to investors or other persons. The information contained in this presentation
Slide 3: The quest for a cure for the common cold
The quest for a cure for the common cold “The search for a cure for the common cold For personal use only resembles in some ways a late 20th-century quest for the holy grail, and although new and remarkable medical discoveries are reported almost daily, medicine still cannot cure the most frequent i
Slide 4: Colds are upper respiratory tract infections caused by viruses
Colds are upper respiratory tract infections (URTI) caused by viruses and spread mainly through airborne microdroplets The viruses enter the nose For personal use only and readily infect nasal cells triggering the symptom complex we call the Hundreds of “common cold” variants from six major virus fa
Slide 5: The constantly evolving pool of viruses that cause the common cold
The constantly evolving pool of viruses that cause the common cold ● 6 main families of viruses Pattern of viruses detected in For personal use only cause colds common cold subjects in 2022/23 ● Rhinovirus is the most common cause, but there are around 200 types of Rhinovirus alone ● Seasonal corona
Slide 6: Why pursue a treatment for the common cold?
Why pursue a treatment for the common cold? It is by far, the most common disease afflicting humankind For personal use only Incidence of diseases worldwide in 20191 ● 17 billion cases worldwide of colds (upper (billions of cases) respiratory tract infection or URTI) each year; 18 17.2 dwarfs all ot
Slide 7: Why is treatment of the common cold so difficult?
Why is treatment of the common cold so difficult? Colds are caused by more than But targeted drugs only work 200 different viruses against one type of virus For personal use only Drug resistance is a problem Cold viruses can readily evolve with antiviral drugs Drugs must be used very early But new d
Slide 8: Povidone-iodine as the basis for a nasal spray
● Povidone-iodine gargles have been very successful in Australia as sore throat treatments; For personal use only in Australia, an estimated 100 million sore throats have been treated with povidone-iodine (PVP-I) gargle since its introduction in 1984 ● PVP-I is an antiseptic that is safe to use in t
Slide 9: Firebrick Pharma history
Firebrick Pharma history HISTORY OF FIREBRICK PHARMA FUNDING HISTORY For personal use only Pre-money ● 2012 Founding Year Funding Firebrick Pharma was founded with the mission to develop Valuation $m a nasal spray based on povidone-iodine to treat the common cold. 2012-2014 Founders - ● 2014-2017 Pr
Slide 10: Firebrick's new strategic direction
For personal use only Firebrick’s new strategic direction: Lower the regulatory hurdle by marketing Nasodine as an antiseptic for nasal use, (not just a treatment for the common cold) This is opening multiple markets for immediate sale and allows consumers and doctors to discover the benefits of Nas
Slide 11: Nasodine as a nasal antiseptic
Nasodine as a nasal antiseptic US advertising Singapore in-store promotion Opens up multiple markets ● Jan 2024: we started commercial-scale For personal use only manufacturing of Nasodine Nasal Spray ● Apr 2024: Launched Nasodine online in US (nasodine.com) as a cosmetic nasal cleanser (no therapeu
Slide 12: People who use Nasodine are our biggest advocates
People who use Nasodine are our biggest advocates 100% 5-star reviews For personal use only People are having great experiences, When used early, it can stop the cold or Don’t let a nasal infection ruin a holiday rebuying and recommending to others help you quickly recover or business trip 11
Slide 13: Plans for FY2026: SE Asia
Plans for FY2026: SE Asia ● Philippines Population (2025) by Country SE Asia » Mar 2025: Successfully manufactured 300 286 For personal use only Nasodine Nasal Spray in the Philippines in anticipation of future approval and launch 250 » Approval is needed by PFDA (Philippines Food & Drug Administrat
Slide 14: Plans for FY2026: USA
Plans for FY2026: USA ● The US business US Quarterly Online Sales FY25 For personal use only » US sales are growing, but currently limited to online sales to consumers (nasodine.com) 30,000 Estimated » US activities are operated through our wholly-owned Q4 subsidiary, Firebrick Pharma, Inc. (FREI);
Slide 15: Published paper reports Nasodine is clinically effective for the common cold
June 5, 2025: Published paper (2019 study) reports Nasodine is clinically effective for the common cold For personal use only Conclusion In the current study, Nasodine 0.5% PVP-I nasal spray demonstrated a consistently positive benefit in reducing overall cold severity outcomes compared with saline
Slide 16: Nasodine benefits over saline nasal spray on symptoms and quality of life
Nasodine benefits over saline nasal spray (SNS) on individual cold symptoms and quality-of-life measures ● Thes results are based For personal use only 30% Symptoms 30% Quality of Life 26% on all subjects, who 25% 25% started treatment on average 40 hours after Nasodine benefit over SNS 20% 20% symp
Slide 17: The world needs Nasodine
The world needs Nasodine A remarkable innovation that will help humankind in many ways For personal use only ● We developed Nasodine as a treatment for the common cold and based on our 2019 Phase III trial, it is significantly effective if used in the first 24 hours after symptom onset. ● Our 2023 C
Slide 18: The longer term vision for Firebrick
The longer term vision for Firebrick For personal use only ● A US business that is selling product to multiple countries online, augmented by drugstore distribution across the US, with the US business generating positive net income ● Nasodine Nasal Spray is available and actively marketed by partner
Slide 19: Bottom lines
Bottom lines For personal use only ● The world needs Nasodine and bringing it to the world is extremely rewarding for everyone involved with Firebrick, including our shareholders ● Firebrick’s risk profile is very low compared to R&D-based life sciences businesses on the ASX – Firebrick is not a ‘bi
Slide 20: For more information visit firebrickpharma.com
For more information visit: www.firebrickpharma.com For personal use only 19